Warfvinges väg 35
About BioArctic ABBioArctic AB is a Swedish privately held research-based biopharmaceutical company founded in 2003. The company’s mission is to provide new and effective treatments for patients with disorders in the central nervous system. Its proprietary technology and dedicated personnel have made it possible to develop new immunotherapeutic approaches to neurodegenerative diseases. We focus on therapy areas with a large medical need such as Alzheimer’s disease, Parkinson’s disease and spinal cord injury.
CEO: Gunilla Osswald
CSO: Christer Möller
CMO: Hans Basun
Please click here for BioArctic job opportunities.
Please click here for clinical trial information.
48 articles with BioArctic AB
BioArctic strengthens its blood-brain barrier technology platform with world leading scientist recruitment
BioArctic AB announced that the company has recruited the internationally renowned scientist Dr. Per-Ola Freskgård to strengthen BioArctic’s development of its technology platform to facilitate passage of antibodies and other biologics across the blood-brain barrier.
BioArctic Receives MEUR 15 Milestone Payment from Eisai for Start of BAN2401 Confirmatory Phase 3 Study in Early Alzheimer's Disease
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company will receive a milestone payment of MEUR 15 from its partner Eisai for the achievement of the first patient being dosed in the global, single confirmatory Phase 3 study (Clarity AD) with BAN2401 in early Alzheimer´s disease.
BioArctic: Alzheimer's Clinical Trials Consortium and Eisai Announce BAN2401 to be Evaluated in Clinical Study for Prevention of Alzheimer's Disease
BioArctic AB informed today that the Alzheimer's Clinical Trials Consortium (ACTC) and BioArctic's partner Eisai have announced the selection of BAN2401 to be evaluated in an upcoming clinical study targeting secondary prevention of Alzheimer's disease (the A45 study).
BioArctic’s partner Eisai initiated Phase 3-study with BAN2401 in Alzheimer’s disease.
Invitation to presentation of BioArctic’s Interim Report for the first quarter of 2019 on May 9, at 9.30 a.m. CET
BioArctic AB to publish the company’s Interim Report for the period January – March 2019 on Thursday, May 9, 2019 at 08:00 a.m. CET.
BioArctic AB announced that the Annual Report for the 2018 fiscal year has been published.
The shareholders in BioArctic AB, corporate identity number 556601-2679 are hereby summoned to the Annual General Meeting to be held on May 9, 2019, at 5 p.m., at Grant Thornton Sweden AB’s offices, Sveavägen 20, Stockholm, Sweden.
BioArctic Receives Grant from Vinnova for a Collaborative Research Project to Increase Brain Uptake of Antibodies
Collaborative research project between industry and academia to develop multi-specific antibodies intended for immunotherapy in central nervous system diseases.
BioArctic’s partner Eisai to give poster presentations on BAN2401 in early Alzheimer’s disease at the AD/PD conference in Lisbon
BioArctic AB announces that its partner Eisai will give poster presentations related to BAN2401 in early Alzheimer’s disease at the 14th International Conference on Alzheimer’s & Parkinson’s Diseases on March 27 in Lisbon, Portugal.
BioArctic's Partner Eisai Initiates the Confirmatory Phase 3 Study of BAN2401 in Early Alzheimer's Disease
BioArctic AB announced that its partner Eisai has initiated the global Phase 3 confirmatory study of BAN2401 in patients with early Alzheimer´s disease.
BioArctic AB comments on the decision by Nasdaq Stockholm to halt trading in BioArctic due to large movements in the share price.
BioArctic AB announced that the first clinical study with ABBV-0805 has started in the U.S. AbbVie is responsible for the clinical development of ABBV-0805.
BioArctic: Eisai Announces Timelines for the Single Confirmatory Phase 3 Study With BAN2401 in Warly Alzheimer's Disease
BioArctic AB informs that Eisai today announced the timelines for the single confirmatory Phase 3 study with BAN2401 in early Alzheimer´s disease patients i.e. mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease.
BioArctic's partner Eisai will initiate BAN2401 confirmatory Phase 3-study in early Alzheimer's disease. AbbVie in-licensed the Parkinson portfolio
BioArctic's Product Candidate SC0806 for Treatment of Patients With Complete Spinal Cord Injury is now in Phase 2
BioArctic AB announced that the first patient in the second panel of the Phase 1/2 study now has been treated with SC0806.
BioArctic: U.S. Food and Drug Administration Approves Investigational New Drug Applicationfor ABBV-0805
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that AbbVie has received approval from the U.S. Food and Drug Administration (FDA) of the Investigational New Drug (IND) application for ABBV-0805.
BioArctic AB to publish the company’s Full Year Report for the period January – December 2018 on Thursday, February 14, 2019 at 08:00 a.m. CET.
BioArctic Announces That Eisai Will Initiate Phase 3 Confirmatory Study With BAN2401 in Early Alzheimer's Disease
BioArctic AB announced that Eisai stated at their Q3 FY2018 Financial Results Meeting on February 4, 2019 that a single Phase 3 confirmatory study of BAN2401 in early Alzheimer´s disease patients is under preparation and planned to be initiated within Eisai's FY2018 i.e. the first quarter 2019.
BioArctic AB announced today that Gunilla Andersson assumes the new position as Senior Director HR in the management team as of January 1, 2019.
BioArctic Outlicenses its Alpha-synuclein Antibody Portfolio for Parkinson's Disease to AbbVie After Receiving Clearance
BioArctic AB announced today that BioArctic and its partner AbbVie (NYSE: ABBV) have received U.S. Federal Trade Commission (FTC) clearance to license BioArctic's alpha-synuclein antibody portfolio for Parkinson's disease and other potential indications to AbbVie.